타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Kisunla (donanemab) |
Overview Company | Eli Lilly |
Overview Modality | ANTIBODY |
Overview Target | N3pG amyloid-beta plaque |
Overview Indication | Early symptomatic Alzheimer's disease with confirmed amyloid pathology |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Plaque-only specificity permits aggressive clearance and pre-specified treatment discontinuation once amyloid PET turns negative. |
Positioning Known limitation | High baseline tau burden limits clinical benefit despite full plaque clearance. |
Positioning Development positioning | First disease-modifying therapy |
MoA Mechanism | Binds the N3pG epitope present in deposited plaque and drives microglial phagocytic clearance, converting amyloid-PET-positive patients to negative within months. |
MoA Biomarker | Amyloid PET centiloid, plasma p-tau217; baseline tau PET stratifies benefit. |
Toxicology Major finding | Boxed warning for ARIA. Infusion-related reactions are common; the modified titration schedule was added to lower ARIA-E incidence. |
Toxicology CRS | N/A |
Clinical Safety signal | Boxed warning for ARIA. Infusion-related reactions are common; the modified titration schedule was added to lower ARIA-E incidence. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Kisunla (donanemab) |
Overview Company | Eli Lilly |
Overview Modality | ANTIBODY |
Overview Target | N3pG amyloid-beta plaque |
Overview Indication | Early symptomatic Alzheimer's disease with confirmed amyloid pathology |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Plaque-only specificity permits aggressive clearance and pre-specified treatment discontinuation once amyloid PET turns negative. |
Positioning Known limitation | High baseline tau burden limits clinical benefit despite full plaque clearance. |
Positioning Development positioning | First disease-modifying therapy |
MoA Mechanism | Binds the N3pG epitope present in deposited plaque and drives microglial phagocytic clearance, converting amyloid-PET-positive patients to negative within months. |
MoA Biomarker | Amyloid PET centiloid, plasma p-tau217; baseline tau PET stratifies benefit. |
Toxicology Major finding | Boxed warning for ARIA. Infusion-related reactions are common; the modified titration schedule was added to lower ARIA-E incidence. |
Toxicology CRS | N/A |
Clinical Safety signal | Boxed warning for ARIA. Infusion-related reactions are common; the modified titration schedule was added to lower ARIA-E incidence. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교